After initial successful evaluation of the circumsporozoite-based vaccine RTS,S/SBAS2, developed by SmithKline Beecham Biologicals with the Walter Reed Army Institute of Research, protective efficacy of several regimens against Plasmodium falciparum challenge was determined. A controlled phase 1/2a study evaluated 1 or 2 standard doses of RTS,S/SBAS2 in 2 groups whose members received open-label therapy and 3 immunizations in blinded groups who received standard, one-half, or one-fifth doses. RTS,S/SBAS2 was safe and immunogenic in all groups. Of the 41 vaccinees and 23 control subjects who underwent sporozoite challenge, malaria developed in 7 of 10 who received 1 dose, in 7 of 14 who received 2 doses, in 3 of 6 who received 3 standard doses, in 3 of 7 who received 3 one-half doses, in 3 of 4 who received 3 one-fifth doses, and in 22 of 23 control subjects. Overall protective efficacy of RTS,S/SBAS2 was 41% (95% confidence interval, 22%-56%;
Africa [2] . The continuing spread of drug-resistant parasites and insecticide-resistant mosquitoes [3] makes the identification of a safe and effective vaccine a high public health priority.
Several malaria vaccine candidates are in preclinical development, but few have entered human clinical trials. Of those that have, some of the most promising have been obtained with the malaria vaccine candidate known as RTS,S/SBAS2, developed by SmithKline Beecham Biologicals with the Walter Reed Army Institute of Research [4] . This vaccine, which targets the pre-erythrocytic stage of the parasite's life cycle, is based on the P. falciparum circumsporozoite (CS) protein and is formulated with a potent proprietary adjuvant known as SBAS2. Previous reports showed that this formulation protected a significant number of malaria-naive subjects from a laboratorybased sporozoite challenge, although the duration of protection appeared to be short-lived [4, 5] . We have continued to expand the clinical database for RTS,S/SBAS2 in an effort to define vaccine doses and schedules that provide optimal protection without significant adverse events. Here we report the results of a phase 1/2a clinical study that evaluated both the dose and the schedule of RTS,S/SBAS2 administration, to characterize further their safety and immunogenicity, and confirmed the ability of the vaccine to protect against sporozoite challenge.
Subjects and Methods
Subjects. Healthy malaria-naive men and women 18-45 years old were recruited and were included or excluded on the basis of standardized criteria used in previous studies of this vaccine [4, 5] .
Vaccine. The antigen component of the vaccine (RTS,S), which contains antibody targets, as well as a number of helper and cytolytic T cell epitopes, has been described elsewhere [4, [6] [7] [8] . The vaccine (SmithKline Beecham Biologicals) was formulated by combining RTS,S with the proprietary adjuvant SBAS2, which consists of an oil-in-water emulsion and the immunostimulants, 3-deacylated monophosphoryl lipid A and QS21 [4, [9] [10] [11] . RTS,S/SBAS2 and SBAS2 were administered to human subjects under a US Food and Drug Administration Investigational New Drug application.
Study design. A multiple-arm trial was designed to study different vaccine dosing regimens. Some subjects were assigned to openlabel groups that received either 1 (group A) or 2 (group B) standard 50-mg doses of RTS,S/SBAS2. Additional subjects were assigned to 4 double-blinded groups, groups C-F, the members of which, respectively, received 3 standard, intermediate (one-half), or low (onefifth) doses of RTS,S/SBAS2 or 3 standard adult doses of a licensed hepatitis B vaccine (Engerix-B, SmithKline Beecham Biologicals). Group A also enrolled control subjects, who received a single dose of SBAS2 adjuvant without RTS,S. Assignment to groups C-F was randomized and was balanced for sex and preimmunization presence of antibodies to hepatitis B surface antigen (HBsAg). The study in these arms was conducted in a double-blind manner.
Vaccines were administered in the deltoid muscle, according to the schedule defined for each group. Subjects in the 2-dose vaccine group received their doses 1 month apart. Although the original protocol specified that the 3-dose groups would receive their doses on a 0-, 1-, and 6-month schedule, the third dose was postponed to 9 months because of logistical difficulties. All subjects who completed the vaccination regimen were asked to undergo sporozoite challenge 2-4 weeks after their final vaccine dose.
Two separate malaria challenges were conducted during this trial. Five SBAS2 adjuvant control subjects were challenged along with group A, as well as 1 nonimmunized infectivity control subject (challenge 1). The adjuvant control subjects received a single standard dose of the SBAS2 adjuvant alone (without malaria vaccine) at the same time as those subjects who received a single dose of RTS,S/SBAS2. Ten other nonimmunized infectivity control subjects were challenged along with groups B-F (challenge 2).
Follow-up and assessment of adverse reactions. Safety was evaluated by assessment of vaccine reactogenicity by use of standardized criteria and grading parameters. Variables recorded included subject-reported symptoms, such as feverishness, malaise, and injection site pain, as well as physician-documented physical findings, such as erythema, warmth, and injection site tenderness. Subjects were observed for 20 min after each immunization and were evaluated at 1, 2, 3, 7, and 14 days after immunization for possible vaccine-related adverse events.
Malaria sporozoite challenge. The ability of the vaccine to protect against malaria infection was determined by laboratorybased sporozoite challenge. Vaccines were considered to protect if the subjects developed no parasitological evidence of P. falciparum infection for 2 months after standardized exposure to the bites of 5 malaria-infected mosquitoes [12] . Cloned, chloroquine-sensitive P. falciparum (3D7 strain) parasites were expanded from a master seed lot and were used to infect laboratory-reared Anopheles stephensi mosquitoes. Sporozoite challenge of both vaccinees and control subjects occurred ∼2-4 weeks after the last vaccine dose in each group [4] , with intensive follow-up occurring for the next 2 months. Subjects who remained asymptomatic and parasite-free for 60 days after the challenge were considered to be protected against malaria. Those subjects who developed patent parasitemia were treated with a standard oral regimen of chloroquine [13] plus other medications as dictated by their symptoms and were followed up until analysis of 3 consecutive daily blood smears showed that the subject was negative for malaria and that all symptoms had resolved.
Immunogenicity analysis. Blood for analysis of both humoral and cellular immune responses was obtained before each immunization and at specific time points during the study. Specific IgG and IgG subclass levels were measured by ELISA with recombinant R32LR as capture antigen for antibodies against tandem repeat epitopes, as described elsewhere [14] [15] [16] [17] . Flanking-region antibody levels, also quantified by ELISA, were reported in optical density (OD) units, the serum dilution yielding an OD of 1.0. The malarial plate antigens used for ELISA were all based on the P. falciparum 3D7 sequence. Antibodies against the HBsAg carrier matrix were measured according to the Hollinger method and were expressed in milli-international units per milliliter [18] . Seroconversion was considered to have occurred if postimmunization antibody titers assessed in triplicate against CS tandem-repeat epitopes exceeded the specific vaccine group mean baseline values plus 2 SD. Serum samples obtained on the day of sporozoite challenge along with preimmune serum samples were analyzed by an indirect fluorescence antibody (IFA) assay, as described elsewhere [17] .
Measurement of T cell responses. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized donor blood by gradient centrifugation on Ficoll-Hypaque (Organon Technika) and were stored in liquid nitrogen until use. PBMC samples were collected before the first vaccination and 2-3 weeks after the last dose of vaccine, which usually coincided with the day of challenge. For proliferative assays, PBMC were thawed, washed, and adjusted to a concentration of cells/mL, as described elsewhere [4] . 6 2 ϫ 10 A total of 0.1 mL was dispensed into triplicate wells of 96-well Ubottom plates. PBMC cultures were stimulated with graded concentrations of RTS,S (0.3 mg, 3 mg, and 30 mg) or HBsAg (0.15 mg/ mL, 1.5 mg/mL, and 15 mg/mL) delivered in 0.1-mL aliquots per well. Control cultures received 0.1 mL of phytohemagglutinin (2 mg/mL) or medium alone. Proliferative responses were measured by the uptake of 3 H-TdR, and responses were expressed as counts per minute [5] .
Statistical methods. A formal data analysis plan was prepared in advance that described in detail the statistical analyses planned for the study. Analyses were performed with SAS software (version 6.12; SAS Institute) and S-PLUS software (version 4.0; MathSoft). Descriptive and graphical statistical methods summarized safety and efficacy by treatment group and compared vaccine groups with control groups. Tabulated frequencies summarized categorical data. For numerical data, the mean, SE, and median were computed. All P values were 2-sided and were computed without corrections for multiplicity. Vaccine efficacy was computed with the standard formula , where I v and I c are the incidence rates in the RTS,S/ E p 1 Ϫ (I /I ) c v SBAS2 vaccine and placebo groups, respectively, and is the I /I c v estimated relative risk (RR). Incidence rates were calculated as the number of subjects with malaria divided by the number of subjects at risk. The 95% confidence intervals (95% CIs) for vaccine efficacy were calculated with asymptotic estimates of the variances of the RR (precision-based estimates) without adjustment for multiple comparisons. Time to malaria was estimated by Kaplan-Meier analysis NOTE. Data are no. (%) of subjects per group who experienced a subjective or documented adverse event in association with any vaccine dose during a 30-day follow-up period. Symptoms attributable to malaria are not included. Injection site pain was the most common subjective complaint, and localized arm tenderness was the most common objective finding in all groups. Vaccine groups are as follows: A (1 standard dose of RTS,S/SBAS2); B (2 standard doses of RTS,S/SBAS2);
C (3 standard doses of RTS,S/SBAS2); D (3 intermediate doses of RTS,S/SBAS2); E (3 low doses of RTS,S/SBAS2); and F (3 doses of hepatitis B vaccine).
with a log-rank test to compare distributions of malaria-free time. The 95% CIs for proportions were calculated by the Clopper-Pearson method, as implemented in StatExact (version 4.1; Cytel). Two exploratory analyses were also performed. First, logistic regression models evaluated the effect on protection of dose and number of injections of RTS,S. Second, receiver operating characteristic curves were constructed to evaluate the sensitivity and specificity of various cutoffs for seroconversion.
Results
Study population. Eighty subjects were enrolled and received у1 dose of RTS,S/SBAS2, SBAS2 adjuvant alone, or hepatitis B vaccine. A safety, reactogenicity, and efficacy control group for the single-dose group A initially consisted of 6 subjects who received only the SBAS2 adjuvant. One of these subjects was not challenged, and an additional nonimmunized control subject was recruited before the first challenge to bring the control group for the first challenge to 6 subjects (challenge 1). The rest of the vaccine groups (groups B-F), plus 10 nonimmunized malarianaive subjects who volunteered to serve as infectivity control subjects, were challenged separately (challenge 2). The 11 infectivity control subjects, who did not receive an injection, were not included in the analyses of vaccine safety and reactogenicity but were included in the vaccine efficacy analysis. Sixty-six (83%) of the subjects received all assigned doses. Dropouts during the study were related primarily to scheduling problems, noncompliance at required follow-up visits, and the length of the study. Although subjects who completed their respective immunization schedule were eligible for the sporozoite challenge, those whom investigators deemed to be unreliable were not offered participation in this phase of the study.
Safety. Table 1 summarizes objective and subjective adverse events, which were most common in the groups that received 11 intermediate or standard dose of RTS,S/SBAS2. No serious adverse event occurred that was attributable to any of the vaccine schedules. All regimens containing the SBAS2 adjuvant were more reactogenic than the control vaccine. No vaccine dose was refused by any of the subjects because of side effects. No clinically important significant alteration in laboratory values was detected after the administration of any immunizations.
Immunogenicity. RTS,S/SBAS2 was highly immunogenic. It induced antigen-specific IgG antibody responses in all subjects who received у1 doses of vaccine. All subjects in groups A-E seroconverted, as determined by measurement of antibodies to CS repeat and C terminal epitopes. Figures 1 and 2 depict group geometric mean IgG antibody responses to CS repeats and CS flanking regions, respectively. Antibodies to CS repeats typically were maximal after 2 vaccine doses had been administered. In groups C-E, responses declined between the second and third doses but returned toward maximal levels after dose 3. Analysis of IgG subclass responses was restricted to measurement of IgG1 and IgG2 antibodies against CS repeats, because only low levels of IgG3 and IgG4 were detected. All groups that received RTS,S/SBAS2 showed IgG1 and IgG2 responses, but IgG1 was the dominant subclass in all groups (data not shown). Antibody responses against the C terminal nonrepeat flanking region increased with each dose of vaccine.
The small size of each group prevents meaningful statistical analyses; however, group E, which received the lowest dose of [4, 5] . Antibody responses against native CS protein associated with sporozoites were measured by IFA assay in serum samples obtained from those subjects who underwent malaria challenge. All preimmune serum samples were negative (titer !50), and all day-ofchallenge serum samples were positive (geometric mean titer [GMT] for all RTS,S/SBAS2 subjects undergoing challenge, 7800; range, 400-102,400). Group GMTs for IFA assay most closely paralleled responses measured against CS repeats by ELISA (table 2) .
RTS,S/SBAS2 is also a potent hepatitis B vaccine. Group mean antibodies against HBsAg shows that у1 standard or intermediate doses of RTS,S resulted in rapid seroconversion (figure 3). Low doses also achieved comparable titers after 3 doses, although the response to 1-2 standard doses was less dramatic. Neither sex nor baseline hepatitis B immune status affected immune responses generated to malarial epitopes (data not shown).
PBMC from subjects who received RTS,S/SBAS2 proliferated in vitro upon exposure to vaccine antigens. Proliferative reactivity against RTS,S and HBsAg before immunization and on the day of challenge revealed a positive correlation between antigen concentration and proliferation that was restricted to the postvaccination samples. Therefore, data are reported (table  3) only for the highest antigen concentrations (RTS,S at 30 mg/ mL and HBsAg at 15 mg/mL). Analysis of the data indicates that responses to RTS,S occurred in both RTS,S-and HBsAgimmunized subjects, probably because of the presence of HBsAg in RTS,S/SBAS2. The responses to RTS,S were higher in the RTS,S/SBAS2-immunized groups than in the hepatitis B-vaccinated control subjects, a finding that is explained by the greater adjuvanticity of SBAS2 versus alum, by a contribution of the CS epitopes to the proliferative response, or both. Responses to HBsAg were uniformly higher in groups that received RTS,S/SBAS2, compared with the hepatitis B-vaccinated control subjects.
Vaccine efficacy. Two separate sporozoite challenges were conducted during this study. Challenge 1 consisted of the 10 single-dose vaccine recipients, 5 SBAS2 adjuvant control subjects, and 1 nonimmunized infectivity control subject. Challenge 2 consisted of 24 subjects from the randomized 3-dose groups, 14 subjects from the open-label, 2-dose group, and 10 nonimmunized, malaria-naive infectivity control subjects. Both challenges were highly infectious; all but 1 of 23 control subjects developed malaria ( ). Pooling the results of both challenges, 18 I p 95% c (44%) of 41 RTS,S/SBAS2 vaccine recipients were protected ( , Fisher's exact test). The point estimates and 95% P p .0006 Because the sample sizes are small, the CIs for the estimates of vaccine efficacy are wide; thus group-to-group comparisons have too little statistical power to provide meaningful conclusions. In all cases where malaria developed, the malaria-free prepatent periods of the control groups were shorter (median, 12 days) than they were for those who received RTS,S/SBAS2 (median, 14 days). Figure 4 presents a Kaplan-Meier survival curve showing the time to malaria in the RTS,S/SBAS2 and control groups. Log-rank tests show that delays in time to infection were unlikely to have occurred by chance ( ). P ! .005 Protection from malaria was not associated with sex or hepatitis B immune status at baseline (data not shown).
Discussion
RTS,S/SBAS2 was safe and well tolerated in all groups. The spectrum of adverse events was consistent with that reported elsewhere [4] . Although fewer adverse events occurred in subjects assigned to the lowest RTS,S/SBAS2 dose group (group Figure 3 . Geometric mean anti-hepatitis B antibodies (mIU/mL) for vaccinated subjects. Antibody concentrations 110 mIU/mL are considered to be protective against hepatitis B infection. Anti-hepatitis B surface antigen responses in all the RTS,S/SBAS2 groups were much greater than those seen in the group that received 3 doses of hepatitis B vaccine. NOTE. A positive proliferative response was defined as an immune count per minute (cpm) that exceeded the appropriate preimmune geometric mean cpm plus 2 SDs. Preimmune data from groups A and B came from those specific groups, whereas pooled preimmune data were used for the randomized groups C-F. CI, confidence interval; HBsAg, hepatitis B surface antigen; ND, not done. E), the overall small numbers of subjects make separating group E from the other groups difficult.
Immunization with RTS,S/SBAS2 induced significant IgG antibody responses directed against the CS repeat. These responses generally paralleled those of antibodies directed against the CS flanking regions, although responses to the flanking regions tended to boost more after the third dose of vaccine. Although there were high and low responders, it is important to note that all vaccine recipients seroconverted after the first dose, which suggests that there is no significant genetic restriction of humoral responses to CS repeats or to the CS flanking region after immunization with RTS,S/SBAS2. These findings are consistent with data from previous studies of RTS,S/SBAS2 [4, 5] .
A strong antibody response directed against CS repeat epitopes is believed to be an important mechanism by which CS subunit vaccines might protect against malaria. Previous human challenge studies with a variety of CS-based subunit vaccines have tended to support this view, but until now, too few subjects have been protected to allow for formal testing of the concept. With a sizable number of challenged and protected subjects available from this study, we attempted to address the issue of whether antibodies to the CS repeat can serve as a surrogate marker for vaccine protective efficacy. A simple approach is to select prospectively a cutoff value below which protection is considered to be unlikely. A value of 20 mg/mL was suggested by data drawn from 10 challenge studies of CS vaccines that we have conducted since 1986. In these trials, only 5 of 108 vaccinated subjects with CS repeat IgG levels below this level were protected from a standardized sporozoite challenge, whereas 14 of 27 vaccinees with antibody levels 120 mg/mL were protected. We therefore explored the effect of prospectively defining a cutoff of 20 mg/mL for seroconversion in the current study and evaluated the relationship between seroconversion and protection. The new seroconversion rates ranged from 60% in group A to 79% in group B, with the other groups at intermediate levels.
Among all challenged subjects who received RTS,S/SBAS2, the recalculated seroconversion rate was 83% in protected subjects and 39% in unprotected vaccinated subjects, a difference that is statistically significant ( , Mantel-Haenszel). Although P p .012 protected subjects tended to have total antirepeat IgG concentrations 120 mg/mL, the converse was not true. The data show no trend of protection with increasing IgG levels, although there may be a trend toward longer prepatent periods. None of the regression models yielded statistically significant findings, and receiver operating characteristic analyses that examined seroconversion cutoffs other than 20 mg/mL did not identify a cutoff that more accurately predicted protection from malaria. Similarly, there was no evidence that high levels of anti-CS flanking region antibodies or lymphocyte proliferation responses correlated independently with protection or prolongation of prepatent periods. This is consistent with the results of a clinical trial of a non-repeat-containing CS vaccine, where induction of CS flanking region antibodies did not result in either protection or delay of patency after sporozoite challenge [19] .
Apart from safety and immunogenicity parameters, the most important property for any malaria vaccine candidate remains its ability to protect against malaria. To this end, the capacity to perform human sporozoite challenges remains an essential feature of malaria vaccine development efforts and is a critical tool for evaluating the efficacy of promising malaria vaccine candidates. Analysis of the efficacy data shows that RTS,S/ SBAS2 given in у1 doses has a measurable protective effect on vaccinated human subjects exposed to sporozoite challenge. Allowing for the relatively small numbers of challenged subjects, it appears that the best efficacy against challenge occurred for the groups that received 2 or 3 standard doses or 3 intermediate doses of RTS,S/SBAS2.
Our use of sufficient numbers of simultaneously challenged infectivity control subjects ensured the validity of each challenge and enabled the detection of partial efficacy through prolongation of the prepatent period. The use of adjuvant control subjects in the first challenge excludes the possibility of nonspecific protective immunity induced by SBAS2. Although we did not have the ability to evaluate additional adjuvant control subjects with the multiple-dose schedules, follow-up studies evaluating 2 different candidate malaria vaccines formulated in SBAS2 adjuvant suggest that the immunity induced by RTS,S/SBAS2 is specific (K.E.K., unpublished data). These studies show a complete absence of protective efficacy or delay in patency, which indicates that a nonspecific effect of the SBAS2 adjuvant, if present, is minimal.
Comparison of the mean prepatent periods for those subjects developing malaria shows that there is a highly significant sta-tistical difference in the prepatent periods for those subjects immunized with RTS,S/SBAS2, relative to concurrent control subjects. This prolongation of the prepatent period in nonprotected RTS,S/SBAS2 recipients is best explained by a reduction in the infectious inoculum of sporozoites, impairment of hepatic schizogony, or both, which results in the release of fewer merozoites from the liver. Davis et al. [20] have suggested a mathematical model that attempts to describe this type of vaccine effect on sporozoites. Pooling all RTS,S/SBAS2 subjects in the study yields an even more striking difference. This delay in patency suggests that, in the setting of preexisting immunity to asexual stage parasites, RTS,S/SBAS2, apart from conferring protection against infection, may improve the clinical outcome of P. falciparum infection by decreasing the initial load of infected erythrocytes and by allowing the immune system to respond more effectively to infection with asexual stage parasites. This potential benefit of the vaccine can best be assessed in ongoing and future efficacy field trials.
The results of this trial confirm the data generated in earlier clinical studies. RTS,S/SBAS2 remains the most promising malaria vaccine candidate tested in humans. Analysis of the data from this and other human studies suggests a vaccine efficacy of 50% when administered in the dose schedules that we have evaluated to date. The safety record and the reproducible protection afforded by RTS,S/SBAS2 provide a solid basis on which to evaluate new dosages, formulations, schedules, and multiple malaria antigen combinations in volunteer sporozoite challenge models and on which to further extend the evaluation to field trials.
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